These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 16623870)

  • 1. Modifying graft immunogenicity and immune response prior to transplantation: potential clinical applications of donor and graft treatment.
    Martins PN; Chandraker A; Tullius SG
    Transpl Int; 2006 May; 19(5):351-9. PubMed ID: 16623870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mixed chimerism achieved by a nonlethal conditioning regimen induces donor-specific tolerance to lung allografts.
    Li S; Salgar SK; Kurimoto Y; Yousem S; Pham SM
    J Surg Res; 2008 May; 146(2):289-97. PubMed ID: 18314139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What can be learned from brain-death models?
    Pratschke J; Neuhaus P; Tullius SG
    Transpl Int; 2005 Jan; 18(1):15-21. PubMed ID: 15612978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
    Strober S
    Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution.
    Rizzieri DA; Koh LP; Long GD; Gasparetto C; Sullivan KM; Horwitz M; Chute J; Smith C; Gong JZ; Lagoo A; Niedzwiecki D; Dowell JM; Waters-Pick B; Liu C; Marshall D; Vredenburgh JJ; Gockerman J; Decastro C; Moore J; Chao NJ
    J Clin Oncol; 2007 Feb; 25(6):690-7. PubMed ID: 17228020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Avenues for immunomodulation and graft protection by gene therapy in transplantation.
    Moore DJ; Markmann JF; Deng S
    Transpl Int; 2006 Jun; 19(6):435-45. PubMed ID: 16771864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Donor reactive regulatory T cells.
    Feng G; Chan T; Wood KJ; Bushell A
    Curr Opin Organ Transplant; 2009 Aug; 14(4):432-8. PubMed ID: 19448539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploiting tolerance processes in transplantation.
    Waldmann H; Cobbold S
    Science; 2004 Jul; 305(5681):209-12. PubMed ID: 15247471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preconditioning with ozone abrogates acute rejection and prolongs cardiac allograft survival in rats.
    Stadlbauer TH; Eisele A; Heidt MC; Tillmanns HH; Schulz S
    Transplant Proc; 2008 May; 40(4):974-7. PubMed ID: 18555093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene therapy in transplantation in the year 2000: moving towards clinical applications?
    Guillot C; Le Mauff B; Cuturi MC; Anegon I
    Gene Ther; 2000 Jan; 7(1):14-9. PubMed ID: 10680010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Living donor kidney transplantation: the effects of donor age and gender on short- and long-term outcomes.
    Øien CM; Reisaeter AV; Leivestad T; Dekker FW; Line PD; Os I
    Transplantation; 2007 Mar; 83(5):600-6. PubMed ID: 17353781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review of nonimmunological causes for deteriorated graft function and graft loss after transplantation.
    Pratschke J; Weiss S; Neuhaus P; Pascher A
    Transpl Int; 2008 Jun; 21(6):512-22. PubMed ID: 18266771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complement and renal transplantation: from donor to recipient.
    Damman J; Schuurs TA; Ploeg RJ; Seelen MA
    Transplantation; 2008 Apr; 85(7):923-7. PubMed ID: 18408568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Individuality: the barrier to optimal immunosuppression.
    Kahan BD
    Nat Rev Immunol; 2003 Oct; 3(10):831-8. PubMed ID: 14523389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recipient age affects long-term outcome and hepatitis C recurrence in old donor livers following transplantation.
    Selzner M; Kashfi A; Selzner N; McCluskey S; Greig PD; Cattral MS; Levy GA; Lilly L; Renner EL; Therapondos G; Adcock LE; Grant DR; McGilvray ID
    Liver Transpl; 2009 Oct; 15(10):1288-95. PubMed ID: 19790152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging science, emerging ethical issues: who should fund innate alloimmunity-suppressing drugs?
    Land WG; Gutmann T; Daar AS
    Acta Chir Belg; 2008; 108(1):73-82. PubMed ID: 18411578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Innate immunity-mediated allograft rejection and strategies to prevent it.
    Land WG
    Transplant Proc; 2007 Apr; 39(3):667-72. PubMed ID: 17445569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apoptotic donor leukocytes limit mixed-chimerism induced by CD40-CD154 blockade in allogeneic bone marrow transplantation.
    Li JM; Gorechlad J; Larsen CP; Waller EK
    Biol Blood Marrow Transplant; 2006 Dec; 12(12):1239-49. PubMed ID: 17162205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of donor age on renal allograft function and survival.
    Resende L; Guerra J; Santana A; Mil-Homens C; Abreu F; da Costa AG
    Transplant Proc; 2009 Apr; 41(3):794-6. PubMed ID: 19376354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.